Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,862 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Sanjay Nayak sold 1,862 shares of Ocular Therapeutix stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.17, for a total transaction of $13,350.54. Following the completion of the sale, the insider now directly owns 281,623 shares in the company, valued at approximately $2,019,236.91. The trade was a 0.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ocular Therapeutix Price Performance

OCUL traded down $0.13 during midday trading on Friday, reaching $8.01. 2,177,691 shares of the company's stock were exchanged, compared to its average volume of 1,399,863. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock has a market capitalization of $1.28 billion, a PE ratio of -6.07 and a beta of 1.51. The business's 50-day moving average price is $7.37 and its 200 day moving average price is $7.90. Ocular Therapeutix, Inc. has a 1-year low of $4.79 and a 1-year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. As a group, equities analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on OCUL. William Blair began coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating on the stock. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a report on Thursday. Needham & Company LLC decreased their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.25.

Hedge Funds Weigh In On Ocular Therapeutix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deep Track Capital LP raised its position in Ocular Therapeutix by 0.9% during the fourth quarter. Deep Track Capital LP now owns 12,836,282 shares of the biopharmaceutical company's stock worth $109,622,000 after acquiring an additional 114,822 shares during the last quarter. Vanguard Group Inc. raised its position in Ocular Therapeutix by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock worth $72,453,000 after acquiring an additional 99,730 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Ocular Therapeutix by 44.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock valued at $38,116,000 after buying an additional 1,600,000 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Ocular Therapeutix by 43.9% in the fourth quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock valued at $25,073,000 after buying an additional 895,304 shares during the last quarter. Finally, Deltec Asset Management LLC raised its position in shares of Ocular Therapeutix by 3.8% in the first quarter. Deltec Asset Management LLC now owns 2,716,373 shares of the biopharmaceutical company's stock valued at $19,911,000 after buying an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.